Randomized, double‐blind placebo‐ and tolterodine‐controlled trial of the once‐daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder

An international, multicentre, randomized double‐blind trial is presented. Patients were randomized to treatment with tolterodine, placebo, and two doses of solifenacin. The authors concluded that the two doses of solifenacin improved urgency and other symptoms of the overactive bladder, with an acc... View More